Invest in the Cannabis Industry with Cannara

We’re changing the narrative in the industry.

We offer premium cannabis, grown from rare genetics, hand-trimmed then slow cured and sold at disruptively low pricing.

We’ve rapidly emerged as one of Canada’s fast-growing producers and we’ve got a bright future ahead of us.

Q3 2026 HIGHLIGHTS

Record quarterly performance: Generated $31.8 million in net revenue, $13.4 million in gross profit before fair value adjustments, $8.5 million in Adjusted EBITDA and $5.7 million in operating cash flow.
Maintained strong profitability: Reported $4.8 million in net income while achieving our 21st consecutive quarter of positive Adjusted EBITDA and 15th consecutive quarter of positive operating cash flow.
Expanded national distribution: Cannara products surpassed 49,000 points of distribution and represented approximately 3.3% of national retail listings, while maintaining an estimated 4.4% national retail market share, demonstrating continued consumer demand and strong product velocity.
Accelerated cultivation expansion: Activated two additional grow zones at Valleyfield, increasing annualized production capacity to over 58,000 kg, with plans to reach approximately 75,000 kg by the end of fiscal 2027—about one year ahead of our original expansion timeline.
Advanced strategic growth initiatives: Completed the acquisition of Medican Organic, secured exclusive Canadian rights to Blue River’s Ampersand™ live rosin infusion technology, and entered our first long-term international supply agreement with Curaleaf, expanding future product and international growth opportunities.